Price to book forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This article provides access to the "Price to book forward" financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) on TradingView. It highlights that the market was closed with no trades at the time of viewing. The page is part of TradingView's comprehensive financial data and analysis tools for stocks.
Enterprise value to EBITDA forward of ANI Pharmaceuticals, Inc. – NASDAQ:ANIP
This article provides financial data for ANI Pharmaceuticals, Inc. (NASDAQ: ANIP), specifically focusing on its enterprise value to EBITDA forward. It indicates that the market was closed at the time of publication, and there were no trades. The content is primarily a data point from TradingView, alongside copyright and product information.
Insider Sell: Stephen Carey Sells Shares of ANI Pharmaceuticals Inc (ANIP)
Stephen Carey, Senior Vice President & Chief Financial Officer of ANI Pharmaceuticals Inc (ANIP), sold 2,850 shares on June 29, 2026, reducing his holdings to 177,543 shares. Over the past year, Carey has sold 63,474 shares, contributing to a total of 50 insider sells and no insider buys for ANIP. Currently, ANI Pharmaceuticals stock is trading at $84.12, and its price-to-GF-Value ratio of 0.85 suggests it is modestly undervalued according to GuruFocus's intrinsic value estimate.
ANI Pharmaceuticals (ANIP) CFO Stephen Carey sells 2,850 shares under Rule 10b5-1 plan
ANI Pharmaceuticals' SVP & CFO, Stephen P. Carey, sold 2,850 shares of common stock at a weighted average price of $84.12 per share, totaling approximately $240,000. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026. Following the sale, Carey still holds 177,543 shares, indicating the sale represents a small portion of his overall stake.
ANI Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ANIP)
This article provides an overview of ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) stock, including its current price, performance, and analyst forecasts. It also details financial actuals and estimates, such as earnings, revenue, net income, and market capitalization, along with frequently asked questions about the company's stock.
ANI Pharmaceuticals: Rare Disease Growth At A Generics Multiple (NASDAQ:ANIP)
ANI Pharmaceuticals is presented as a speculative buy due to its transformational growth from Cortrophin Gel, a rare disease treatment. Management projects Cortrophin revenue to reach $540M-$575M by 2026, shifting the company's focus and potentially leading to a re-rating of its stock. The article suggests a fair value of $108, representing a 30% upside, provided Cortrophin's growth and the expansion into gout treatment succeed.
ANIP Forecast — Price Target — Prediction for 2027
This article provides a forecast for ANI Pharmaceuticals, Inc. (ANIP) stock, including analyst price targets and future predictions. It details current stock performance, historical highs and lows, market capitalization, volatility, and upcoming earnings dates. The information presented is not investment advice and encourages readers to conduct their own research.
ANIP Forecast — Price Target — Prediction for 2027
This article provides a forecast for ANI Pharmaceuticals, Inc. (ANIP) stock, including analyst price targets, historical highs and lows, and upcoming earnings dates. It also details the company's financial performance, such as recent EPS and revenue figures, net income, and EBITDA. Key information about the company's dividend policy and employee count is also included.
ANI Pharmaceuticals (ANIP) Stock Could Be 29.5% Below Fair Value After Recent Pullback
ANI Pharmaceuticals (ANIP) stock recently pulled back, showing a mixed short-term performance despite a 21.25% total shareholder return over the past year. The company is considered undervalued, trading at $79.49 against a fair value estimate of $112.71, driven by significant growth potential for Cortrophin Gel. However, its P/E ratio of 20.1x is higher than the US Pharmaceuticals industry average, prompting investors to consider both the growth narrative and valuation risks.
ANI Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $114.17, Implies 44% Upside
ANI Pharmaceuticals, Inc. (ANIP) stock has seen its average 12-month price target raised from $112.71 to $114.17 by 6 analysts. This updated target indicates a potential upside of approximately 44% from the June 18 closing price. The consensus rating for ANIP remains "Buy" across all covering analysts.
ANI Pharmaceuticals Inc (ANIP) Earnings Forecast: Future EPS & Revenue Growth Estimates
ANI Pharmaceuticals Inc (ANIP) has an earnings forecast score of 8.50, ranking 34th in the Pharmaceuticals industry. Analysts have a consensus price target of $107.50 for ANIP, with expectations for strong revenue growth and a "Buy" rating based on the opinions of 7 analysts. The company's expected revenue for the next quarter is $262.14 million, and its EPS for the upcoming quarter is projected at $2.01.
ANI Pharmaceuticals Inc (ANIP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for ANI Pharmaceuticals Inc (ANIP), categorizing its sales by business segments and geographical regions. As of April 6, the company's revenue heavily relies on generic pharmaceutical products and rare disease pharmaceutical products. The United States accounts for the vast majority of its revenue, highlighting a strong domestic market focus.
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock By Investing.com
Meredith Cook, SR. VP, General Counsel & Secretary at ANI Pharmaceuticals Inc. (NASDAQ:ANIP), recently sold 500 shares of the company's common stock for $41,015. The sale was executed under a Rule 10b5-1 trading plan and occurred on June 12, 2026, with Cook retaining 77,890 shares. This transaction comes as ANIP has seen a 31% return over the past year and analysts consider the stock undervalued despite its strong financial health.
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock By Investing.com
Meredith Cook, SR. VP, General Counsel & Secretary at ANI Pharmaceuticals Inc., recently sold 500 shares of company stock totaling $41,015. The sale was executed under a Rule 10b5-1 trading plan and leaves Cook with 77,890 shares. This transaction occurred after the company reported strong Q1 2026 financial results, exceeding market expectations, and with analysis suggesting the stock is undervalued.
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock
Meredith Cook, SR. VP, General Counsel & Secretary at ANI Pharmaceuticals Inc. (NASDAQ:ANIP), recently sold 500 shares of company stock for a total of $41,015. This transaction follows the company's strong first-quarter 2026 financial results, which exceeded market expectations with a 41.38% higher EPS and higher revenue. The stock has seen a 31% return over the past year.
Ani Pharmaceuticals Sr. VP Cook sells $41,015 in stock
Meredith Cook, SR. VP, General Counsel & Secretary at ANI Pharmaceuticals Inc. (NASDAQ:ANIP), recently sold 500 shares of the company’s common stock for a total of $41,015 at $82.03 per share. This transaction, executed under a Rule 10b5-1 trading plan, leaves Cook with 77,890 shares. The sale occurred after the stock delivered a 31% return over the past year, and the company recently reported strong Q1 2026 results, surpassing market expectations for EPS and revenue.
ANI Pharmaceuticals (ANIP) VP sells 500 shares under 10b5-1 plan
ANI Pharmaceuticals' Senior Vice President, General Counsel, and Secretary, Meredith Cook, sold 500 shares of common stock at an average price of $82.03 per share. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 15, 2025. Following the sale, Cook directly holds 77,890 shares of ANIP.
ANI Pharmaceuticals (ANIP) Stock Valuation After Recent Momentum And Cortrophin Growth Prospects
ANI Pharmaceuticals (ANIP) has recently shown positive stock performance and is considered undervalued by analysts, with a fair value estimated at $109.88 per share. This valuation is driven by expected growth in Cortrophin Gel, which targets a large market due to an aging population and increasing chronic diseases. However, potential risks include pricing pressure, payer access issues, and generic competition.
Insider Sell: Thomas Haughey Sells 2,000 Shares of ANI Pharmaceu
Thomas Haughey, a Director at ANI Pharmaceuticals Inc (ANIP), sold 2,000 shares of the company on June 8, 2026. This transaction leaves him with 38,878 shares. Over the past year, Haughey has sold 21,341 shares, and the company has seen 49 insider sells with no buys, indicating an insider selling trend.
Ani Pharmaceuticals director Thomas Haughey sells $161,760 in stock
ANI Pharmaceuticals director Thomas Haughey sold 2,000 shares of company stock for $161,760 on June 8, 2026, as part of a 10b5-1 trading plan. This comes after he acquired 4,357 restricted shares on May 21, 2026. The company recently reported strong financial results for Q1 2026, exceeding analyst expectations for EPS and revenue, contributing to its "GREAT" financial health score and over 30% stock price increase in the past year.
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027
ANI Pharmaceuticals director Matthew J. Leonard was granted 4,357 restricted shares of common stock as part of his equity-based compensation. These shares, awarded at no cash cost, will vest in full on May 21, 2027, provided he remains eligible. Following this grant, Leonard directly holds 11,221 shares of ANI Pharmaceuticals common stock, indicating a routine compensation award.
Director Jeanne Thoma receives 4,357-share grant at ANI Pharmaceuticals (ANIP)
ANI Pharmaceuticals director Jeanne Thoma was granted 4,357 shares of common stock as a restricted stock award, with no cash paid per share. This grant increases her direct holdings to 27,762 common shares. The restricted stock award is set to vest in full on May 21, 2027, provided all conditions are met.
ANI Pharmaceuticals (ANIP) director awarded 4,357 restricted shares vesting in 2027
ANI Pharmaceuticals director Antonio R. Pera received a grant of 4,357 restricted shares of Common Stock as part of his equity compensation, with a vesting date of May 21, 2027. These shares were awarded at no cash cost to him. Following this transaction, Pera directly holds a total of 27,017 shares of ANI Pharmaceuticals Common Stock.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANI Pharmaceuticals (ANIP) is transitioning towards high-margin specialty revenues, primarily driven by Purified Cortrophin Gel, leading to increased earnings and an improved 2026 outlook. The company's valuation appears appealing at 9.75x forward twelve-month earnings, which is significantly below industry averages and its historical median. However, investors need to weigh this upside against potential risks such as intensifying market competition and substantial customer concentration.
Should You Buy ANI Pharmaceuticals at 9.8x Forward Earnings?
ANI Pharmaceuticals (ANIP) is shifting towards high-margin specialty revenues, driven by Cortrophin Gel, with strong earnings growth and a positive 2026 outlook. However, the company faces risks including increasing competition in key markets and significant customer concentration. Despite these challenges, ANIP's strong Q1 2026 performance, solid cash position, manageable debt, and a new share repurchase program signal management's confidence in its future growth trajectory, making its current valuation appear undervalued given its forward earnings multiple.
Ani Pharmaceuticals SVP & CFO Stephen Carey sells $264,960 in stock
Stephen P. Carey, SVP and CFO of ANI Pharmaceuticals Inc., sold 3,312 shares of common stock for $264,960 after exercising stock options for the same number of shares. The transactions were conducted under a Rule 10b5-1 trading plan. The company recently reported strong Q1 2026 financial results, exceeding market expectations, and analysts maintain current ratings.
CenterBook Partners LP Purchases Shares of 19,226 ANI Pharmaceuticals, Inc. $ANIP
CenterBook Partners LP recently acquired a new stake of 19,226 shares in ANI Pharmaceuticals, valued at approximately $1.52 million. This comes after ANI Pharmaceuticals reported strong quarterly earnings, beating consensus estimates with an EPS of $2.05 and a 20.5% increase in revenue year-over-year. Despite recent insider share sales, analysts maintain a "Moderate Buy" rating for the stock with an average price target of $107.33.
[Form 4] ANI PHARMACEUTICALS INC Insider Trading Activity
This article reports on an insider trading activity for ANI Pharmaceuticals Inc. (ANIP) by SVP & CFO Stephen P. Carey. The Form 4 filing details that Mr. Carey sold 3,312 shares for $265,000, exercised options, and that the transactions were part of a Rule 10b5-1 trading plan. The article provides a summary of the trade and the full SEC Form 4 document.
[144] ANI PHARMACEUTICALS INC SEC Filing
This article reports on an SEC Form 144 filing by ANI Pharmaceuticals Inc. (ANIP) regarding the proposed sale of 2,000 shares of common stock with an aggregate market value of $162,220. The filing details the acquisition of these securities through restricted stock awards and indicates the sale is to occur on June 8, 2026, via Morgan Stanley Smith Barney LLC. The article also provides company overview, latest news, and SEC filing history for ANIP.
What ANI Pharmaceuticals (ANIP)'s Recall, Raised Guidance and Buybacks Could Mean For Shareholders
ANI Pharmaceuticals recently initiated a Class II recall for Estradiol Gel 0.1% due to defective packets but simultaneously reported strong Q1 2026 results, raised its full-year 2026 revenue guidance to US$1.08 billion - US$1.14 billion, and launched a US$100 million share repurchase program. The company's investment narrative focuses on Cortrophin Gel and rare disease products, with the recall viewed as a contained operational issue amidst broader expansion plans. Analyst opinions vary, with some modeling even higher revenues and earnings for the company by 2029.
ANI Pharmaceuticals (ANIP) Jefferies Global Healthcare Conference 2026 Summary
ANI Pharmaceuticals (ANIP) presented at the Jefferies Global Healthcare Conference 2026, highlighting its strategic transformation into a leading rare disease company, with rare disease assets projected to account for 60% of revenues by 2026. The company provided 2024 revenue guidance of $1.08–$1.14 billion and strong growth expectations for its key rare disease assets, Cortrophin Gel and ILUVIEN. ANI Pharmaceuticals also detailed its capital allocation priorities, including M&A in rare disease and continued R&D in generics.
ANIP (NASDAQ: ANIP) broker files Form 144 for 11,862-share sale
Morgan Stanley Smith Barney LLC Executive Financial Services has filed a Form 144 notice for a proposed sale of 11,862 shares of ANI Pharmaceuticals (NASDAQ: ANIP) common stock. The sale comprises 3,312 shares from an option exercise dated June 5, 2026, and 8,550 shares from restricted stock awards dated March 31, 2018, with an aggregate reported value of $939,470.40. This filing indicates affiliate dispositions, though exact cash-flow treatment and distribution methods are not detailed.
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
ANI Pharmaceuticals announced that its CEO, Nikhil Lalwani, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026. The event will be webcast live and archived on the company's website. ANI Pharmaceuticals is a biopharmaceutical company focused on rare diseases, generics, and brands.
ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
ANI Pharmaceuticals, Inc. announced that CEO Nikhil Lalwani will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Wednesday, June 3, 2026. A live and archived webcast of the event will be available on the company's website. ANI Pharmaceuticals is a diversified biopharmaceutical company focused on rare diseases, generics, and branded products.
Penn Capital Management Company LLC Increases Stake in ANI Pharmaceuticals, Inc. $ANIP
Penn Capital Management Company LLC significantly increased its stake in ANI Pharmaceuticals, Inc. during the fourth quarter, now owning 137,394 shares valued at approximately $10.86 million. This increase follows ANI Pharmaceuticals reporting better-than-expected Q1 results with strong EPS and revenue growth. Despite a recent downgrade from Zacks Research to a "hold" rating, analysts generally view the stock as a "Moderate Buy" with an average target price of $107.33.
ANI Pharma CEO joins Jefferies health conference fireside chat June 3
ANI Pharmaceuticals announced that CEO Nikhil Lalwani will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3, 2026, at 3:45 p.m. ET. A webcast of the event will be available on the company's investor relations website for 90 days. This engagement follows recent positive developments for ANIP, including FDA approvals, product launches, and strong financial results.
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program
ANI Pharmaceuticals has increased its revenue outlook for 2026, projecting sales between $1.08 billion and $1.14 billion, up from its previous estimate of $1 billion. This revised forecast is partly driven by the anticipated launch of Purified Cortrophin Gel, with peak annual net revenues now expected to reach $300 million to $350 million. Concurrently, the company has announced a new $100 million share repurchase program, reflecting confidence in its financial performance and commitment to shareholder value.
ANI Pharmaceuticals, Inc. $ANIP Shares Sold by Lisanti Capital Growth LLC
Lisanti Capital Growth LLC significantly reduced its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by 63.2% in the fourth quarter, selling 52,175 shares and retaining 30,379 shares valued at $2.4 million. Despite this, ANI Pharmaceuticals reported strong quarterly results, with EPS of $2.05 beating expectations and revenue increasing by 20.5% year over year to $237.46 million. The stock maintains a "Moderate Buy" consensus rating with a target price of $107.33, though recent insider sales and one analyst downgrade have been noted.
ANI Pharmaceuticals raises 2026 revenue outlook to $1.08B-$1.14B while launching $100M share repurchase program
ANI Pharmaceuticals has increased its revenue guidance for 2026 to a range of $1.08 billion to $1.14 billion. Concurrently, the company announced the initiation of a $100 million share repurchase program. This move signals confidence in future financial performance and aims to enhance shareholder value.
ANI Pharmaceuticals (ANIP) Q1 2026 Earnings: Revenue Beat, Guidance, and Stock Drop - News and Statistics
ANI Pharmaceuticals (ANIP) reported a strong Q1 2026 with revenues of $237.5 million, a 20.5% year-over-year increase, significantly beating analysts' expectations by 14%. Despite this "exceptional quarter" with beats on both EPS and revenue, the stock fell by 5.5% to $79.31, suggesting investor expectations may have surpassed Wall Street's published projections. The pharmaceuticals sector as a whole saw mixed results, with revenues collectively beating estimates by 1.5% but share prices declining by an average of 5.5% post-earnings.
ANI Pharmaceuticals (NASDAQ: ANIP) investors back directors, pay and stock plan
ANI Pharmaceuticals (NASDAQ: ANIP) stockholders approved all proposals at their 2026 Annual Meeting, including the election of seven directors, ratification of Ernst & Young LLP as auditor, and advisory approval of executive compensation. They also approved the Amended and Restated 2022 Stock Incentive Plan and opted for annual advisory votes on executive pay. The meeting's results, detailing voting figures for each proposal, reinforce investor confidence in the company's governance and compensation practices.
ANI Pharmaceuticals Q1 2026 earnings preview
This article is a preview of ANI Pharmaceuticals' first-quarter 2026 earnings. However, the provided content is empty, so no further details about the preview are available.
ANI Pharmaceuticals (ANIP) SVP sells 2,772 common shares
ANI Pharmaceuticals' Senior Vice President of Generics, Ori Gutwerg, executed an open-market sale of 2,772 common shares on May 12, 2026, at a price of $79.50 per share. Following this transaction, he directly owns 78,696 shares of ANI Pharmaceuticals common stock. The sale, classified as a moderate impact with negative sentiment, totaled $220,374.
UBS Group AG Has $11.90 Million Position in ANI Pharmaceuticals, Inc. $ANIP
UBS Group AG significantly reduced its stake in ANI Pharmaceuticals (NASDAQ:ANIP) by 74.4% in Q4, now holding 150,779 shares valued at $11.9 million. Despite this, ANI Pharmaceuticals reported strong Q1 results, with EPS of $2.05 against an expected $1.28 and a 20.5% year-over-year revenue increase to $237.46 million, and reiterated its FY 2026 EPS guidance. Insider selling by SVP Ori Gutwerg and VP Meredith Cook was noted, while analysts maintain a "Moderate Buy" rating with an average price target of $107.33.
ANIP Valuation: Does 9.8x Forward P/E Offer Upside?
ANI Pharmaceuticals (ANIP) is trading at a forward P/E of 9.83x, significantly below its industry, sector, and S&P 500 benchmarks, and its own five-year median. The company's Rare Disease franchise is showing strong momentum, and management has raised its 2026 revenue and EBITDA guidance. Despite underperforming year-to-date against the broader market, its low valuation suggests potential upside if its specialty revenue growth continues and ophthalmology business recovers.
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANI Pharmaceuticals is strategically shifting its focus toward Rare Disease and Brands, with Cortrophin Gel and Iluvien driving growth, while generics serve as a cash-flow engine. The company is implementing a 2026 playbook to restore Iluvien's growth after 2025 reimbursement and inventory challenges and expand its specialty presence. Facing intensifying competition and customer concentration risks, ANI aims to meet specific growth targets for Cortrophin and Iluvien, manage generics launches, and navigate margin pressure from royalty-bearing products.
How ANI’s Raised 2026 Guidance And Buyback Plan At ANI Pharmaceuticals (ANIP) Has Changed Its Investment Story
ANI Pharmaceuticals reported strong Q1 2026 results, raising its 2026 revenue guidance to $1.08–$1.14 billion and authorizing a $100 million share repurchase program. This move, combined with the accelerating growth in its Rare Disease segment, particularly Cortrophin Gel, reinforces a narrative of higher margins and earnings per share. However, the company faces risks related to payer and pricing pushback for ACTH therapies and a heavy dependence on a few flagship products.
ANI Pharmaceuticals: Rare Disease Shift and the 2026 Playbook
ANI Pharmaceuticals is strategically shifting its focus towards Rare Disease and Brands, with Cortrophin Gel and Iluvien as key growth drivers, while positioning generics as a cash flow engine. The company is actively working to restore Iluvien's growth after 2025 disruptions and plans numerous generic launches for 2026. This repositioning comes with competitive challenges from major players like AbbVie and Regeneron and risks associated with customer concentration.
[144] ANI PHARMACEUTICALS INC SEC Filing
ANI Pharmaceuticals Inc. has filed Form 144 with the SEC, indicating a proposed sale of 10,000 shares of common stock with an aggregate market value of $795,600. The shares were acquired through an open market purchase on March 21, 2022. The filing, dated May 13, 2026, also notes that no securities of the issuer were sold by the person for whose account the securities are to be sold within the past three months.
People moves: Shelly Hubbard joins Lowe’s as ANI Pharmaceuticals brings in Irina Koffler
Shelly Hubbard has been appointed as the new vice president, head of investor relations at Lowe’s, after a tenure at Pentair. Concurrently, ANI Pharmaceuticals announced Irina Koffler as its new vice president, investor relations, transitioning from LifeSci Advisors. Other significant hires include Claire Ross at Colgate-Palmolive, Bill Seymour at James Hardie, Sven Köpsel at Sartorius, and Danah Alomar at Mobily, all taking on key investor relations roles.
